Oslo, Norway, 9 March 2022 – Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, today announces that an abstract has been accepted for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting.
The abstracts show ONCOS-102 drives pro-inflammatory modulation of the tumor micro-environment in PD-1 refractory melanoma tumors. ONCOS-102 is associated with efficient viral gene expression and strong, sustained activation of immune-related genes, which may be targets for future combinations of ONCOS-102 and immune-modulators beyond PD-1/PD-L1 inhibitors.
The abstract has been released on the AACR website today (https://www.aacr.org/meeting/aacr-annual-meeting-2022/abstracts/). The poster is scheduled for presentation Monday 11 April 2022 and will be available on Targovax’s website after the presentation.
|
Poster title: |
Modulation of immune gene expression by intra-tumoral oncolytic adenovirus ONCOS-102 is associated with clinical response in anti-PD-1 refractory/resistant melanoma |
|
Date and time: |
Monday 11 April 2022, 13:30- 17:00 CDT / 20:30-24:00 CET |
|
Location: |
New Orleans Convention Center, Exhibit Halls D-H, Poster Section 31 |
|
Session category: |
Clinical research excluding trials |
|
Session title: |
Immune response to therapies / immune monitoring and clinical correlate |
|
Poster number: |
1983 |
|
Presenter: |
Thomas Birkballe Hansen, VP Research, Targovax |
About AACR
The AACR Annual Meeting is the focal point of the cancer research community, where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share the latest advances in cancer science and medicine. From population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy; the AACR Annual Meeting highlights the work of the best minds in cancer research from institutions all over the world.
For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@targovax.com
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com
Media enquires:
Andreas Tinglum – Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no
About Targovax
Activating the patient's immune system to fight cancer
Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors. Targovax’s focus is to activate the patient’s immune system to fight cancer, and thereby bring benefit to cancer patients with few available treatment alternatives. Targovax is assessing its product candidates in different cancer indications, including melanoma, mesothelioma and colorectal cancer, and has demonstrated a favorable safety and tolerability profile.
Targovax’s lead clinical candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect cancer cells and activate the immune system to fight the cancer. On the back of very encouraging clinical data in several indications, both as monotherapy and in immunotherapy and chemotherapy combinations, the next development step for ONCOS-102 will be to further improve immune activation and clinical response in melanoma patients resistant to PD1 checkpoint blockade.